L&C Bio (290650) In-Depth Analysis: Re2O Capacity Expansion and Valuation Review
L&C Bio is a medical materials company primarily engaged in human tissue implants. In Q1 2026, the company reported consolidated revenue of KRW 30.3B (≈$20.2M) (YoY +70.6%) and operating profit of KRW 6B (≈$4.0M) (OPM 19.8%), signaling entry into a profitability recovery phase. The ECM-based skin booster 'Re2O' is emerging as a new growth driver, with production capacity expansion and global regulatory approvals progressing in parallel.
1. Company Overview and Core Business
L&C Bio (290650) is a medical materials specialist company primarily engaged in human tissue implants (skin and bone grafts). On a consolidated basis, the company recorded annual revenue of 855억원 (≈$57.1M) and operating profit of 42억원 (≈$2.8M) (OPM 5.0%) in FY2025. In Q1 2026, consolidated revenue of 303억원 (≈$20.2M) (YoY +70.6%) and operating profit of 60억원 (≈$4.0M) confirmed profitability improvement. On a standalone basis, Q1 revenue was 238억원 (≈$15.9M) (+63.4%) with operating profit of 65억원 (≈$4.3M) (OPM 27.2%, YoY +546.8%), with standalone profitability exceeding the consolidated level. Subsidiaries include Global Medical Research Center, L&C ES, and L&C Medicare, with overseas business expansion underway through its China entity (L&C China).
📌 Q1 2026 Standalone OPM 27.2% · Consolidated OPM 19.8% — Core business profitability recovery confirmed
2. Core Product Competitiveness Analysis
Human tissue implants are the flagship product line, recording standalone revenue of 561억원 (≈$37.4M) in 2025, with growth to approximately 841억원 (≈$56.1M)*4 projected in the business report for 2026. The ECM (extracellular matrix)-based skin booster 'Re2O' is projected to grow from 60억원 (≈$4.0M) annually in 2025 to a combined domestic and overseas target of 500억원 (≈$33.4M)*3 in 2026. Clinical results published in an international journal (IJMS) in February 2026 quantitatively demonstrated Re2O's Structural Volumizing efficacy across all 14 evaluation parameters compared to hyaluronic acid-based controls. The direct sales ratio has improved from the previous ~30% range to ~40%, enhancing the channel mix, with production capacity scheduled to expand in stages from the current 35,000 units/month to 80,000 units/month in May 2026 and 150,000 units/month in November 2026.
| Category | Details |
|---|---|
| Position | Domestic ECM skin booster leader — mechanism differentiation backed by clinical data (IJMS-published) |
| Competitive Advantage | phADM Structural Volumizing clinical evidence secured; direct sales ratio at ~40%, improving channel profitability |
| Competitive Disadvantage | Rising dependence on Re2O as a single product — potential for increased revenue volatility in the event of regulatory approval delays |
3. Valuation Analysis
On a 2025 consolidated basis, the company recorded a net loss of KRW 129.1B (≈$86.2M) — a swing to deficit — making Trailing PER calculation impossible. The primary driver of the loss is a fair-value loss on the conversion right derivative embedded in the 3rd-series unsecured private convertible bonds (face value KRW 60B (≈$40.1M)) issued in April 2025, which is a non-cash accounting item. Based on the 2026F EPS of KRW 999 (≈$0.7)*1, the Forward PER stands at approximately 60.7x, which is 2.1x higher than the sector-average Forward PER of 28.8x. PBR is 7.73x, and Eugene Investment & Securities has set a target price of KRW 80,000 (≈$53.4) by applying a PER of 30x to the projected 2027 controlling-interest net profit of KRW 74B (≈$49.4M) — implying 32.0% upside from the current price of KRW 60,600 (≈$40.5).
📌 Forward PER of 60.7x*1 represents a 111% premium over the sector average (28.8x) — indicating the Lituo high-growth scenario is already fully priced in
| Metric | Current | Sector Average | Interpretation |
|---|---|---|---|
| Forward PER | 60.7x*1 | 28.8x | 2.1x premium over sector average |
| PBR | 7.73x | — | Reflects high market value relative to assets |
| OPM (1Q26 Consolidated) | 19.8% | — | Profitability recovery vs. 2025 OPM of 5.0% |
| Debt-to-Equity Ratio | 119.0% | — | Debt level elevated after reflecting convertible bonds |
4. Risk Factors and Monitoring Points
There is a concurrent risk of a gap between Lituo's capacity expansion (150,000 units/month by November) and actual demand, alongside potential delays in overseas regulatory approval timelines. Upon conversion of the 3rd-series convertible bonds, up to 3,284,634 additional shares may be issued, resulting in dilution for existing shareholders. The risk of further fair-value losses related to the Chinese subsidiary (L&C China) also remains, and the interest burden under the current debt-to-equity ratio of 119.0% warrants ongoing monitoring in light of the interest rate environment.
- ⚠️ Slowdown in revenue growth due to delays in Lituo's overseas regulatory approvals (target: 10 countries by 1H 2026)
- ⚠️ Dilution risk of up to 3,284,634 shares upon conversion of the 3rd-series unsecured private convertible bonds (KRW 60B (≈$40.1M))
- 📌 Lituo quarterly revenue (quarterly tracking of progress toward the 2026F annual target of KRW 50B (≈$33.4M)*3)
- 📌 Standalone OPM trend (quarterly tracking of deviation vs. Value-up disclosure target operating margin of 32%*2)
5. Recent DART Disclosures
Two disclosures — the corporate value enhancement plan and the business report — are directly relevant to this analysis. The medium-to-long-term targets and projections stated in the disclosures have been incorporated into the footnotes of this report.
| 날짜 | 공시명 | 요약 |
|---|---|---|
| 2026-04-01 | Corporate Value Enhancement Plan | Officially disclosed a medium-to-long-term plan targeting an overseas revenue share of 38% and an operating profit margin of 32%, along with a shareholder value enhancement initiative. No specific target dates were stated. |
| 2026-03-31 | Business Report (15th Fiscal Year, FY2025) | Filed on DART: a report containing finalized consolidated results for FY2025, projected 2026 consolidated revenue of 1,185억원 (≈$79.1M), and projected human tissue graft revenue of 841억원 (≈$56.1M). |
L&C Bio's core business profitability has been confirmed as of Q1 2026 (consolidated OPM 19.8%), with the quarterly revenue accumulation pace of Re2O and the progress of overseas regulatory approvals serving as the key variables determining the company's future earnings trajectory.
📎 출처 및 추정 근거
- *1 Based on Yuanta Securities' 2026 earnings estimate (report dated 2026-03-03), applying controlling interest net profit of KRW 24.3B (≈$16.2M) divided by 24,342,063 shares outstanding, giving EPS of KRW 999 (≈$0.67). Forward PER = current price KRW 60,600 (≈$40.5) ÷ EPS KRW 999 ≈ 60.7x.
- *2 Based on the Corporate Value Enhancement (Value-up) Plan disclosure (2026-04-01). Specific achievement timeline and target year not specified.
- *3 Yuanta Securities' 2026 Re2O revenue estimate (report dated 2026-03-03): Domestic KRW 40B (≈$26.7M) + Overseas KRW 10B (≈$6.7M) = Total KRW 50B (≈$33.4M).
- *4 2026 human tissue implant revenue forecast of KRW 84.1B (≈$56.1M) as stated in the DART business report (15th fiscal year, FY2025).
- *5 USD equivalents (≈$) are approximate, calculated at 1 USD = 1,498 KRW (as of 2026-05-16, source: Yahoo Finance via TradeAlert).
본 보고서는 정보 제공 목적이며 투자 권유가 아닙니다. 투자 결정은 본인 책임입니다.
댓글 없음:
댓글 쓰기